Zuranolone

FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day

In 2022, when the US Food and Drug Administration (FDA) was reeling under the impact of the pandem

Job cuts double in 2023; Pfizer, BMS, Novartis, Biogen downsize to cut costs

The year 2023 has seen considerable job cuts by biopharmaceutical companies. While layoffs have be